AZD9793 clinical trials

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1)

This study is testing a new medicine, AZD9793, for adults with advanced solid cancers, especially liver cancer. It's looking at how safe the medicine is, how it moves through the body, and if it can help shrink tumours. It's an early-stage study, meaning it's one of the first times this medicine is being used in people.